188 related articles for article (PubMed ID: 16922642)
1. Clinical pharmacology of etoricoxib.
Capone ML; Tacconelli S; Patrignani P
Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):269-82. PubMed ID: 16922642
[TBL] [Abstract][Full Text] [Related]
2. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
Croom KF; Siddiqui MA
Drugs; 2009 Jul; 69(11):1513-32. PubMed ID: 19634927
[TBL] [Abstract][Full Text] [Related]
3. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.
Patrignani P; Capone ML; Tacconelli S
Expert Opin Pharmacother; 2003 Feb; 4(2):265-84. PubMed ID: 12562317
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
[TBL] [Abstract][Full Text] [Related]
6. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Curtis SP; Ko AT; Bolognese JA; Cavanaugh PF; Reicin AS
Curr Med Res Opin; 2006 Dec; 22(12):2365-74. PubMed ID: 17265571
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Baraf HS
Curr Pharm Des; 2007; 13(22):2228-36. PubMed ID: 17691996
[TBL] [Abstract][Full Text] [Related]
8. Etoricoxib.
Matsumoto AK; Cavanaugh PF
Drugs Today (Barc); 2004 May; 40(5):395-414. PubMed ID: 15319795
[TBL] [Abstract][Full Text] [Related]
9. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
Feng X; Tian M; Zhang W; Mei H
PLoS One; 2018; 13(1):e0190798. PubMed ID: 29320568
[TBL] [Abstract][Full Text] [Related]
11. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
[TBL] [Abstract][Full Text] [Related]
12. Etoricoxib.
Cochrane DJ; Jarvis B; Keating GM
Drugs; 2002; 62(18):2637-51; discussion 2652-3. PubMed ID: 12466002
[TBL] [Abstract][Full Text] [Related]
13. Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Cannon CP; Curtis SP; Bolognese JA; Laine L;
Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.
Takemoto JK; Reynolds JK; Remsberg CM; Vega-Villa KR; Davies NM
Clin Pharmacokinet; 2008; 47(11):703-20. PubMed ID: 18840026
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
17. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
[TBL] [Abstract][Full Text] [Related]
19. Etoricoxib and the treatment of ankylosing spondylitis.
Lories RJ
Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1599-608. PubMed ID: 23126318
[TBL] [Abstract][Full Text] [Related]
20. A case report on toxic epidermal necrolysis with etoricoxib.
Kameshwari JS; Devde R
Indian J Pharmacol; 2015; 47(2):221-3. PubMed ID: 25878388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
